ARCT icon

Arcturus Therapeutics

10.20 USD
+0.77
8.17%
At close Apr 2, 4:00 PM EDT
After hours
9.51
-0.69
6.76%
1 day
8.17%
5 days
-15.28%
1 month
-34.95%
3 months
-40.25%
6 months
-59.97%
Year to date
-40.25%
1 year
-68.34%
5 years
-19.43%
10 years
79.26%
 

About: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

Employees: 176

0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 46

0.32% more ownership

Funds ownership: 98.05% [Q3] → 98.36% (+0.32%) [Q4]

1% less call options, than puts

Call options by funds: $2.94M | Put options by funds: $2.98M

11% less funds holding

Funds holding: 164 [Q3] → 146 (-18) [Q4]

26% less capital invested

Capital invested by funds: $615M [Q3] → $452M (-$163M) [Q4]

52% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 31

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$41
302%
upside
Avg. target
$55
437%
upside
High target
$68
567%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
Whitney Ijem
23% 1-year accuracy
10 / 43 met price target
567%upside
$68
Buy
Maintained
10 Mar 2025
HC Wainwright & Co.
Ed Arce
36% 1-year accuracy
40 / 111 met price target
488%upside
$60
Buy
Maintained
7 Mar 2025
Wells Fargo
Yanan Zhu
11% 1-year accuracy
1 / 9 met price target
390%upside
$50
Overweight
Maintained
7 Mar 2025
BTIG
Thomas Shrader
0% 1-year accuracy
0 / 8 met price target
302%upside
$41
Buy
Initiated
28 Jan 2025

Financial journalist opinion

Based on 4 articles about ARCT published over the past 30 days

Neutral
Seeking Alpha
3 weeks ago
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne - President and Chief Executive Officer, Director of the Board Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Lili Nsongo - Leerink Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Myles Minter - William Blair Joohwan Kim - Canaccord Genuity Pete Stavropoulos - Cantor Tom Shrader - BTIG Thomas Yip - HCW Yanan Zhu - Wells Fargo Yale Jen - Laidlaw & Company Operator Good day, everyone, and welcome to today's Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 weeks ago
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago.
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Neutral
Business Wire
3 weeks ago
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updates. “We continue to progress our flagship rare disease programs and look forward to sharing meaningful Phase 2 in.
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
Neutral
Business Wire
4 weeks ago
Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Leerink's Global Healthcare Conference 2025 in Miami, on Wednesday, March 12, 2025, at 10:40 a.m. Eastern Time. Webcast link can be found under Inve.
Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025
Neutral
Business Wire
1 month ago
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time.
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
Neutral
PRNewsWire
1 month ago
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials WALTHAM, Mass. and SAN DIEGO , Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older.
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Neutral
Business Wire
1 month ago
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-.
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Neutral
Business Wire
1 month ago
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutic.
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Neutral
Business Wire
2 months ago
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of “KOSTAIVE® for Intramuscular Injection,” a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan. Meiji Seika Pharma and ARCALIS Co., Ltd. (Headquarters: Minami-soma City, Fukushima.
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
Neutral
Business Wire
2 months ago
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time. Webcast link can be found.
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
Charts implemented using Lightweight Charts™